Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Change in Receivables: 2015-2025

Historic Change in Receivables for Aytu Biopharma (AYTU) over the last 11 years, with Sep 2025 value amounting to $2.1 million.

  • Aytu Biopharma's Change in Receivables rose 533.05% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.2 million, marking a year-over-year increase of 238.22%. This contributed to the annual value of $7.6 million for FY2025, which is 246.68% up from last year.
  • Aytu Biopharma's Change in Receivables amounted to $2.1 million in Q3 2025, which was up 144.33% from -$4.7 million recorded in Q2 2025.
  • Aytu Biopharma's 5-year Change in Receivables high stood at $10.5 million for Q1 2025, and its period low was -$6.5 million during Q3 2021.
  • In the last 3 years, Aytu Biopharma's Change in Receivables had a median value of -$118,000 in 2023 and averaged $643,455.
  • Per our database at Business Quant, Aytu Biopharma's Change in Receivables plummeted by 2,775.45% in 2022 and then soared by 2,025.42% in 2024.
  • Aytu Biopharma's Change in Receivables (Quarterly) stood at $1.3 million in 2021, then slumped by 277.60% to -$2.4 million in 2022, then surged by 95.04% to -$118,000 in 2023, then spiked by 2,025.42% to $2.3 million in 2024, then soared by 533.05% to $2.1 million in 2025.
  • Its last three reported values are $2.1 million in Q3 2025, -$4.7 million for Q2 2025, and $10.5 million during Q1 2025.